The department of radiology provides clinical service to Michigan Medicine, which includes the physically-connected University Hospital, Taubman outpatient center, C.S. Mott Children’s Hospital, the von Voigtlander Women’s Hospital, Frankel Cardiovascular Center, and Rogel Cancer Center on the main campus. As more healthcare continues to move from the hospital to the outpatient environment, our ambulatory care outpatient imaging centers have expanded to nine locations in southeastern Michigan, providing state of the art imaging to our patients closer to home. Our faculty and trainees also provide radiology services to patients at the nearby Ann Arbor Veterans Administration Hospital.
Events
Calling all DR and IR Radiology Applicants!
Join us for our Radiology Residency Virtual Open House. Meet our DR and IR Program Directors, Chairs of the Selection Committee and some current DR and IR residents.
Musculoskeletal Ultrasound at Michigan Medicine: Upper Extremity Fundamentals
This two-day course will provide dedicated instruction in musculoskeletal ultrasound of the upper extremity including didactic lectures and supervised hands-on workshops with ultrasound scanning of live models. The content of this course will include a comprehensive review of anatomy and pertinent pathology of the upper extremities. Topics will
31st Annual Radiology in the Desert 2025
Arizona Biltmore, A Waldorf Astoria Resort | Scottsdale, Arizona
This five-day course will provide a broad overview of selected radiology/imaging subjects of particular importance to diagnostic radiologists in clinical practice. A broad range of lecture topics, with emphasis on practical applications, will be presented. More information
News
Gary Luker, MD appointed as Faculty Director of the Microscopy Core
Karl Jepsen, M.D., Ph.D., associate dean for research, recently announced the appointment of
Atonco and University of Michigan Announce Collaboration on Phase 1-2a Clinical Study of ATO-101™
Atonco, a French biotechnology company, and University of Michigan Health today announced a collaborative agreement to conduct a Phase 1-2a clinical study evaluating Atonco's ATO-101™ ([211At] At-anti-CA-IX antibody) targeted alpha therapy candidate in non-muscle invasive bladder cancer (NMIBC).